Theratechnologies To Present At The Canaccord Genuity 40th Annual Growth Conference On August 12, 2020

Montreal, Canada – July 30, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that Philippe Dubuc, the Senior Vice President and Chief Financial Officer of Theratechnologies, will present at the Canaccord Genuity Growth Conference on Wednesday, August 12, 2020 at 9:30 a.m. ET.

Theratechnologies Reports That Tesamorelin Improves Liver Health

Sub-analysis of MGH study helps better demonstrate how tesamorelin reduces liver fat  Positive impact of tesamorelin on oxidative phosphorylation, inflammation, tissue repair and cell division  Montreal, Canada – July 23, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce new data that further support the potential role …Lire la suite

Recording of the Annual Meeting of Shareholders’ Speeches

Today’s Annual Meeting of Shareholders was mistakenly ended by the operator of the virtual platform after the formal part of the meeting. Speeches from Ms. Dawn Svoronos, Chair of the Board, and Mr. Paul Lévesque, President and Chief Executive Officer, which were supposed to be delivered during the informal part of the meeting, have been …Lire la suite

Announcements In Conjunction With Theratechnologies Annual Meeting

Montreal, Canada – July 16, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today held its annual meeting of shareholders. As part of the meeting, shareholders proceeded to elect the below candidates to the Company’s Board of Directors for a one-year term and elected KPMG LLP, as the Company’s auditors …Lire la suite

Theratechnologies Confirms Bioequivalence Of New Tesamorelin Formulation

sBLA expected to be filed in early 2022  Seven-day multidose vial and room temperature stability allow for the potential use of tesamorelin with a multidose pen injector  Montreal, Canada – July 7, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that it has successfully completed a …Lire la suite

Theratechnologies Announces Ibalizumab Inhibits HIV-2 In Vitro

Montreal, Canada – July 6, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that data presented at the 23rd International AIDS Conference virtual meeting, demonstrates that ibalizumab is active in vitro against group A and group B HIV-2.

New Data Show Theratechnologies’ SORT1+ Technology Is Effective In Many Treatment-Resistant Cancers

Peptide-drug conjugates TH1902 and TH1904 show significant reduction in the formation of vasculogenic mimicry by targeting the sortilin receptor  Curcumin shows increased anticancer activity when conjugated to proprietary peptide  SORT1+ technology significantly widens therapeutic window of traditional cytotoxic cancer treatments  Montreal, Canada – June 22, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a …Lire la suite